Aligning Clinical Value with PACT Act Operational Priorities

Bottom Line:

The PACT Act significantly scaled the VHA’s care mission. Manufacturers succeed by aligning their clinical data with the system's operational goal of providing efficient, high-volume Veteran care.

The PACT Act of 2022 represents the largest expansion in VA beneficiaries in a generation, fundamentally altering the VHA’s scope of responsibilities and its operational priorities. With millions of new Veterans now eligible for care, the health system is managing a significant increase in the rapid processing of claims and toxic exposure screenings alongside its ongoing clinical services. For manufacturers, success in supporting Veterans diagnosed with diseases caused by toxic exposures is no longer measured solely by efficacy data or technical specs. Instead, success for these disease states is defined also by the ability to support the Veteran’s journey from screening to treatment without adding operational friction to an already strained system.

This statute simplifies the path to benefits by establishing a presumptive link between specific military service and over twenty toxic-exposure-related conditions. This presumptive link eliminates the legal and medical need for Veterans to prove their service caused their illness, requiring only a formal diagnosis and evidence of qualifying service to trigger access to care.

To understand the limitations of traditional sales narratives in this environment, manufacturers must first recognize how the federal system differs from the commercial market. In a private healthcare setting, one metric of success is driven by the powerful hook of market share incentivized by innovations designed to attract patient volume or promotion of faster recovery times. The VHA, however, prioritizes long-term outcomes and systemic efficiency because its success is defined by its capacity to manage the total health of the Veteran population over a lifetime.

When a manufacturer presents a data-heavy dossier focused on efficacy in a vacuum, they are losing the plot. Every minute a clinician spends navigating non-standard administrative workarounds for a new therapy is time lost in direct patient care. In this environment, the value of an improved outcome is only fully realized when it integrates seamlessly with existing workflows. As such, sales narratives must shift to include how a product is effective, an operational accelerative, and how its clinical data is mapped to the VHA’s specific diagnostic and documentation requirements.

VHA best utilizes innovations that harmonize with its mandated administrative requirements. By showing that a therapy reinforces the VHA’s mission of efficiency within a value proposition narrative, manufacturers can ensure their clinical value is translated into system-wide utilization.

PACT Act Value Proposition Checklist

[ ] Documentation Gap: Does your clinical narrative align with specific PACT Act administrative requirements?

[ ] Workflow Friction: Have you identified the specific points where your therapy can alleviate the clinician's documentation burden?

[ ] Capacity Analysis: Did you quantify how your innovation supports high-volume Veteran care without increasing staff requirements?

[ ] Systemic Efficiency: Does your value proposition address throughput and longitudinal health?